29 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Article Searches
American Tower Corporation (AMT) UBS Global Media & Communications Conference https://seekingalpha.com/article/4655906-american-tower-corporation-amt-ubs-global-media-and-communications-conference?source=feed_sector_transcripts Dec 04, 2023 - American Tower Corporation (NYSE:NYSE:AMT) UBS Global Media & Communications Conference December 4, 2023 2:15 PM ETCompany ParticipantsSteven Vondran -...
Verizon Communications Inc. (VZ) UBS Global Media and Communications Conference (Transcript) https://seekingalpha.com/article/4655818-verizon-communications-inc-vz-ubs-global-media-and-communications-conference-transcript?source=feed_sector_transcripts Dec 04, 2023 - Verizon Communications Inc. (NYSE:NYSE:VZ) UBS Global Media and Communications Conference December 4, 2023 8:15 AM ETCompany ParticipantsHans Vestberg -...
Swiss regulator calls for more powers after Credit Suisse collapse https://www.cnbc.com/2023/12/19/swiss-regulator-calls-for-more-powers-after-credit-suisse-collapse.html Dec 19, 2023 - Switzerland's financial regulator on Tuesday called for greater legal powers and vowed to adapts its approach in the wake of the Credit Suisse collapse.
UBS cuts Cytokinetics to neutral, sees takeout valuation at $105 https://seekingalpha.com/news/4057887-ubs-cuts-cytokinetics-to-neutral-sees-takeout-valuation-at-105?source=feed_sector_healthcare Jan 24, 2024 - UBS has downgraded Cytokinetics (CYTK) to neutral, commenting that it believes some of the potential M&A premium has already been baked into the stock’s price. Read more here.
UBS Group: Upside Depends On Growing Book Value https://seekingalpha.com/article/4665637-ubs-group-upside-depends-on-growing-book-value?source=feed_tag_editors_picks Jan 28, 2024 - UBS Group AG is the last major Swiss bank after acquiring Credit Suisse for $3 billion in 2023. See why I rate UBS stock as a hold for now.
UBS reports mixed Q4 results; confirms financial targets, reinstates share buyback in 2H24 https://seekingalpha.com/news/4062951-ubs-gaap-eps-of--009-misses-by-242-revenue-of-1086b-beats-by-90m?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news Feb 05, 2024 - UBS (UBS) reports 4Q/FY23 results and confirms financial targets, plans to propose $0.70 dividend per share, +27% Y/Y, and to reinstate share repurchases in 2H24. Q4 GAAP EPS of -$0.09 mi..
Gold prices to hit $2,200 and silver could 'really shine' this year, UBS says https://seekingalpha.com/news/4062949-gold-prices-to-hit-2200-and-silver-could-really-shine-this-year-ubs-says?utm_source=feed_news_all&utm_medium=referral&feed_item_type=news Feb 05, 2024 - Gold and silver prices are expected to rise further in 2024 as the Federal Reserve eventually will start cutting interest rate, UBS precious metals strategist Joni teves says.
UBS beats earnings expectations, announces up to $1 billion share buyback https://www.cnbc.com/2024/02/06/ubs-beats-earnings-expectations-announces-up-to-1-billion-share-buyback.html Feb 06, 2024 - Swiss banking giant UBS on Tuesday narrowly beat fourth-quarter earnings expectations and announced that it would recommence share buybacks worth $1 billion in the second half of the year.
UBS starts Biohaven at buy, cites diverse pipeline https://seekingalpha.com/news/4064106-ubs-starts-biohaven-at-buy-cites-diverse-pipeline?source=feed_sector_healthcare Feb 07, 2024 - UBS has initiated coverage of Biohaven (BHVN) with a buy rating, citing its attractive valuation and diverse pipeline. The investment bank said it was “bullish
UBS cuts BioXcel to neutral; cites regulatory issues, financing https://seekingalpha.com/news/4069650-ubs-cuts-bioxcel-to-neutral-cites-regulatory-issues-financing?source=feed_sector_healthcare Feb 21, 2024 - UBS has downgraded BioXcel Therapeutics (BTAI) to neutral, citing too much uncertainty about the company’s financing, regulatory alignment with the FDA, and end

Pages: 123

Page 1>